Myjoy Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.71 Cr
as on 24-10-2024
- Paid Up Capital ₹ 1.95 Cr
as on 24-10-2024
- Company Age 13 Year, 22 Days
- Last Filing with ROC 31 Mar 2023
- Revenue 719.11%
(FY 2023)
- Profit 313.62%
(FY 2023)
- Ebitda 358.25%
(FY 2023)
- Net Worth 52.78%
(FY 2023)
- Total Assets 774.46%
(FY 2023)
About Myjoy Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.71 Cr and a paid-up capital of Rs 1.95 Cr, as per Ministry of Corporate Affairs (MCA) records.
Manoj Nevatia and Manoj Singh serve as directors at the Company.
- CIN/LLPIN
U24232WB2011PTC169959
- Company No.
169959
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Nov 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Myjoy Pharmaceuticals Private Limited offer?
Myjoy Pharmaceuticals Private Limited offers a wide range of products and services, including Brain & Nervous System Drugs, Psychotherapeutic Agents, Pharma Ingredients & Raw Materials, Vitamin Powder API, Animal Medicines & Health Care, Anthelmintics, Chemical Reagents & Catalysts, Potassium Salts, Insecticides and Pesticides, Pesticide Intermediate.
Who are the key members and board of directors at Myjoy Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manoj Nevatia  | Director | 29-Mar-2019 | Current |
| Manoj Singh | Director | 05-May-2014 | Current |
Financial Performance and Corporate Structure Insights of Myjoy Pharmaceuticals.
Myjoy Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 719.11% increase. The company also saw a substantial improvement in profitability, with a 313.62% increase in profit. The company's net worth Soared by an impressive increase of 52.78%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Myjoy Pharmaceuticals?
In 2023, Myjoy Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Myjoy Pharmaceuticals?
Myjoy Pharmaceuticals has a workforce of 907 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Myjoy Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Myjoy Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
